Compare Nutanix Inc (NTNX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Sana Biotechnology Inc — how do they compare? Nutanix Inc trades at $74.59 (market cap $19.78B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Nutanix Inc is far larger — about 23.6× Sana Biotechnology Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Sana Biotechnology Inc for 23 Days on average.
| NTNX | SANA | |
|---|---|---|
Market Cap | $19.78B | $836.71M |
Volume | 1,717,619 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $73.42 | $5.92 |
52-Week Low | $34.41 | $2.68 |
Typical Hold Time | 17 Days | 23 Days |
Enterprise Value | $18.94B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $74.63, up 1.65% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.54B in 2025 and a net income margin of 52.81% in 2026, supported by leadership recognition in Gartner Magic Quadrant reports (GlobeNewsWire, 2026-09-16).
Outlook remains positive with a consensus price target of $76.11, though high valuation ratios like EV/EBITDA of 46.22 and an overbought RSI near 89.09 pose risks. Growth drivers include external storage and AI initiatives, but investor caution is warranted due to competitive pressures and supply-chain constraints noted in recent news (MarketBeat, 2026-09-14).
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
